Three months ago, Core Scientific delivered the deal its shareholders had been waiting for: a partnership with AMD worth more than $14 billion in base contracted revenue that finally broke the company's dependence on a single customer. The market's response since then has been to sell the stock by nearly a third. That gap between a transformed contract book and a sharply lower share price is what makes the third-quarter report, due before the open on November 5, worth close attention. The question is no longer whether demand exists. It is whether Core Scientific can build and fund what it has already sold.

Wall Street expects revenue of about $179 million, more than double the $81.1 million reported a year ago and roughly 9% above last quarter's $164.2 million. Consensus calls for earnings of roughly breakeven, a big improvement on the year-ago loss of $0.46 per share but a step down from last quarter's $0.18. Given how volatile this company's GAAP bottom line has been, revenue and colocation economics are the cleaner read on whether the business is tracking.

The revenue number matters because management told investors to expect another step-up in colocation sales this quarter. Billable capacity jumped to 437 megawatts by mid-July, about 200 megawatts more than the prior quarter and ahead of the company's own schedule. Colocation revenue reached $137 million in the second quarter, and with that higher capacity in place for the full September period, the colocation line should grow faster than the total. Bitcoin mining, which is being deliberately wound down, will keep shrinking and partly mask that progress. A clean beat would come from colocation revenue clearly outpacing the mining runoff. A disappointment would be any sign that new megawatts are coming online slower than the July pace suggested. Investors should also look for evidence that CoreWeave sites are moving toward the 80% to 85% cash gross profit target management raised earlier this year.

The bigger tests sit beyond the income statement. The initial 530 megawatts for AMD across five sites will require roughly $6 billion, which management plans to raise through project bonds. On the last call, executives acknowledged a backup in interest rates and a digestion period in AI-related credit markets. They also disclosed build costs of $11 million to $12 million per megawatt, higher than the CoreWeave-era figure, citing labor scarcity and tariffs. Progress on financing terms, any further movement in per-megawatt costs, and updates on the plan to spend up to $1 billion on roughly 500 megawatts of speculative capacity will likely move the stock more than the quarterly revenue figure. Investors will also want an update on the more than 2 gigawatts of new site pipeline and AMD's reservation rights for up to about 2 additional gigawatts.

Sentiment has warmed modestly, moving from a bearish reading heading into the last report to mildly bullish now, but the price action tells a harsher story. Shares trade at $14.27, well below the 200-day moving average near $19.69 and close to the bottom of the post-earnings range of $12.31 to $23.60. That entire range sits below the prior quarter's low of $19.89, showing how far the market has repriced the risks of funding and execution.

That setup arguably lowers the bar for a relief move, but only if management addresses the right worry. Hitting the revenue number would confirm that delivery remains on track. Keeping the AMD story intact, however, depends on showing that the $6 billion financing can be secured on workable terms and that rising build costs will not erode the returns that made the deal transformational in the first place.